DE69334186D1 - Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen - Google Patents

Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen

Info

Publication number
DE69334186D1
DE69334186D1 DE69334186T DE69334186T DE69334186D1 DE 69334186 D1 DE69334186 D1 DE 69334186D1 DE 69334186 T DE69334186 T DE 69334186T DE 69334186 T DE69334186 T DE 69334186T DE 69334186 D1 DE69334186 D1 DE 69334186D1
Authority
DE
Germany
Prior art keywords
mage
hla
gene
presented
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334186T
Other languages
English (en)
Other versions
DE69334186T2 (de
Inventor
Thierry Boon-Falleur
Der Bruggen Pierre Van
Plaen Etienne De
Christophe Lurquin
Catia Traversari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25471275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69334186(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/037,230 external-priority patent/US6235525B1/en
Priority claimed from US08/073,103 external-priority patent/US5462871A/en
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of DE69334186D1 publication Critical patent/DE69334186D1/de
Publication of DE69334186T2 publication Critical patent/DE69334186T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
DE69334186T 1992-08-31 1993-08-30 Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen Expired - Lifetime DE69334186T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US938334 1992-08-31
US07/938,334 US5405940A (en) 1992-08-31 1992-08-31 Isolated nonapeptides derived from MAGE genes and uses thereof
US37230 1993-03-26
US08/037,230 US6235525B1 (en) 1991-05-23 1993-03-26 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US08/073,103 US5462871A (en) 1992-08-31 1993-06-07 Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US73103 1993-06-07

Publications (2)

Publication Number Publication Date
DE69334186D1 true DE69334186D1 (de) 2007-12-27
DE69334186T2 DE69334186T2 (de) 2008-09-11

Family

ID=25471275

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69334186T Expired - Lifetime DE69334186T2 (de) 1992-08-31 1993-08-30 Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen

Country Status (2)

Country Link
US (3) US5405940A (de)
DE (1) DE69334186T2 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US6222012B1 (en) * 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
EP0658113B1 (de) * 1992-08-31 2004-10-20 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
AU702517B2 (en) * 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5997870A (en) 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
JPH10511639A (ja) * 1994-09-30 1998-11-10 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 腫瘍拒絶抗原前駆体または腫瘍拒絶抗原を含有する組成物ならびにアジュバント及び／又は成長因子
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5759783A (en) * 1995-03-14 1998-06-02 Ludwig Institute For Cancer Research Method of screening for cancer by detecting messenger RNA for a MAGE-XP gene
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5939526A (en) * 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US5827073A (en) * 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US7297331B2 (en) * 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
WO1997049817A1 (en) * 1996-06-25 1997-12-31 The Ludwig Institute For Cancer Research Brain glycogen phosphorylase cancer antigen
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6156317A (en) * 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
PT970206E (pt) 1997-01-27 2008-10-28 Ludwig Inst Cancer Res Ácidos nucleicos lage-1 associados a tumores
US6794131B1 (en) * 1998-01-27 2004-09-21 Ludwig Institute For Cancer Research Lage-1 tumor associated nucleic acids
US6087441A (en) 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US5879892A (en) * 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6210886B1 (en) 1998-02-04 2001-04-03 Ludwig Institute For Cancer Research Method for diagnosing multiple myeloma by determining tumor rejection antigen precursors
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6245525B1 (en) * 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
WO1999058658A2 (en) * 1998-05-13 1999-11-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
AU6226100A (en) * 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US6632435B1 (en) * 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
DK1230268T3 (da) * 1999-11-18 2010-02-08 Epimmune Inc Heteroklitiske analoger af klasse I-epitoper
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001041788A1 (en) * 1999-12-10 2001-06-14 Epimmune, Inc. INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
EP1244465A4 (de) * 1999-12-21 2005-01-12 Epimmune Inc Induzierung von zellulärer immunantwort gegen prostatakrebsantigenen mittels peptid- und nukleinsäureverbindungen
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US7205104B2 (en) * 2000-03-24 2007-04-17 Eppendorf Array Technologies Sa (Eat) Identification of biological (micro) organisms by detection of their homologous nucleotide sequences on arrays
US7829313B2 (en) * 2000-03-24 2010-11-09 Eppendorf Array Technologies Identification and quantification of a plurality of biological (micro)organisms or their components
US7875442B2 (en) * 2000-03-24 2011-01-25 Eppendorf Array Technologies Identification and quantification of a plurality of biological (micro)organisms or their components
US7202026B2 (en) * 2000-03-24 2007-04-10 Eppendorf Array Technologies Sa (Eat) Identification of a large number of biological (micro)organisms groups at different levels by their detection on a same array
US20080085515A1 (en) * 2000-03-24 2008-04-10 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by detection of their nucleotide sequences on arrays
AU5810201A (en) * 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
EP1164201A1 (de) * 2000-06-14 2001-12-19 Facultés Universitaires Notre-Dame de la Paix Umgekehrter nachweis zur Identifizierung und/oder Quantifizierung von Nukleotid-Zielsequenzen mittels Biochips
CA2422506A1 (en) * 2000-09-08 2002-03-14 Epimmune Inc. Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
AU2002214624A1 (en) 2000-10-20 2002-05-06 City Of Hope Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CN1313617C (zh) * 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
EP1496939B1 (de) 2002-04-09 2007-08-15 Sanofi Pasteur Limited Modifizierte cea nucleinsäure und expressionsvektoren
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
EP2292638A3 (de) 2002-09-27 2011-03-23 Ludwig Institute For Cancer Research MAGE2-Antigen-Peptide und Verwendung davon
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
EP1609107A4 (de) * 2003-03-28 2006-08-30 Idm Pharma Inc Verfahren zur identifizierung optimaler peptidepitopvarianten
EP1756147A2 (de) * 2004-06-01 2007-02-28 Innogenetics N.V. Peptide zur induktion einer t-lymphozyten antwort gegen hepatitis c virus
US7338763B2 (en) * 2004-06-02 2008-03-04 Eppendorf Array Technologies S.A. Method and kit for the detection and/or quantification of homologous nucleotide sequences on arrays
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
EP2305827A1 (de) * 2005-11-14 2011-04-06 Université Laval Krebsantigen MAGE-A9 und Verwendungen davon
CA2848209C (en) * 2011-09-15 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
CA3069017A1 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Immunostimulatory fusion molecules and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141742A (en) * 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
WO1992002543A1 (en) * 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
US5462871A (en) 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof

Also Published As

Publication number Publication date
DE69334186T2 (de) 2008-09-11
US5405940A (en) 1995-04-11
US6034214A (en) 2000-03-07
US6488932B1 (en) 2002-12-03

Similar Documents

Publication Publication Date Title
DE69334186D1 (de) Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen
ATE378406T1 (de) Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
DE3787002D1 (de) Synthetische peptide, die zellulaere immunitaet gegen den aids-virus und dessen proteine erzeugen.
DE69202207D1 (de) Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan.
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
DE69303223T2 (de) Elastische, flüssigkeitgedämpfte Lager und die Montage solcher Lager
SG93791A1 (en) Synthetic polynucleotides
NO950660D0 (no) Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav
DE59104877D1 (de) Elektronenenergiefilter, vorzugsweise vom Alpha- oder Omega-Typ.
DE59400536D1 (de) Längenverstellbare Säule für Stühle, Tische od.dgl.
DE59401899D1 (de) Längenverstellbare Säule für Stühle, Tische o.dgl.
ES2133412T3 (es) 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.
DE3782010T2 (de) Vom calcitonin-gen abgeleitete peptidderivate.
SE9604348D0 (sv) Användning av hydroxyguanidiner
FI974640A0 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
IT1260450B (it) Sistema di assemblaggio di coperture metalliche integrali piegate a canale e del relativo supporto spiegato a pantografo, come pure prodotto che ne risulta
MX9602718A (es) Hidrofluoroalcanos como solventes de limpieza y desengrasado.
DK0719276T3 (da) Ïstradiolestre med stærk oral virkning samt farmaceutiske præparater med indhold deraf
ITMI912757A1 (it) PROCEDIMENTO PER PURIFICARE 1, 1, 1-TRIFLUORO-, 2, 2 DICLOROETANO DALLyISOMERO 1, 1, 2-TRIFLUORO-1, 2-DICLOROETANO.
DE9316381U1 (de) Befestigung für Wege, Plätze u.dgl.
MX9603516A (es) Derivados de oxima y su uso como pesticidas.
DE59504407D1 (de) Längenverstellbare Gasfeder für Stühle, Tische o.dgl.
ITRM920305A0 (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
DE59205402D1 (de) Längenverstellbare Säule für Tische, Stühle od.dgl.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition